Literature DB >> 17295846

Review article: the burden of hepatic encephalopathy.

F F Poordad1.   

Abstract

Hepatic encephalopathy, a challenging complication of advanced liver disease, occurs in approximately 30-45% of patients with cirrhosis and 10-50% of patients with transjugular intrahepatic portosystemic shunt, while minimal hepatic encephalopathy affects approximately 20-60% of patients with liver disease. Although the total direct and indirect costs of hepatic encephalopathy have not been formally quantified, data from the Healthcare Cost and Utilization Project suggest that hepatic encephalopathy-related hospitalizations are associated with substantial costs. In 2003, there were over 40 000 patients hospitalized in the United States for a primary diagnosis of hepatic encephalopathy, resulting in total charges of approximately $932 million. Furthermore, trends over the past 10 years suggest that the burden of hepatic encephalopathy is increasing, as indicated by increases in hospital admissions and higher charges per stay. Because of inconsistencies in coding for hepatic encephalopathy, the prevalence and cost data from this data source are believed to significantly underestimate the true burden of hepatic encephalopathy. In addition, expenditures for physician fees and out-patient care, as well as indirect costs attributable to lost work days and decreased productivity, have not been quantified. Thus, there is need for future studies to more accurately define the burden of hepatic encephalopathy, including minimal hepatic encephalopathy.

Entities:  

Mesh:

Year:  2007        PMID: 17295846     DOI: 10.1111/j.1746-6342.2006.03215.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  87 in total

1.  Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis.

Authors:  Yunhyeong Lee; Chulho Kim; Ki Tae Suk; Hui Chul Choi; Chang Seok Bang; Jai Hoon Yoon; Gwang Ho Baik; Dong Joon Kim; Min Uk Jang; Jong Hee Sohn
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

Review 2.  Complications of end-stage liver disease.

Authors:  Giulia-Anna Perri; Houman Khosravani
Journal:  Can Fam Physician       Date:  2016-01       Impact factor: 3.275

3.  Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Authors:  C S Landis; M Ghabril; V Rustgi; A M Di Bisceglie; B Maliakkal; D C Rockey; J M Vierling; J Bajaj; R Rowell; M Santoro; A Enriquez; M Jurek; M Mokhtarani; D F Coakley; B F Scharschmidt
Journal:  Dig Dis Sci       Date:  2016-01-19       Impact factor: 3.199

4.  Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study.

Authors:  Vijay P B Grover; Mary M E Crossey; Julie A Fitzpatrick; Brian K Saxby; Roberta Shaw; Adam D Waldman; Marsha Y Morgan; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2015-08-08       Impact factor: 3.584

Review 5.  Minimal hepatic encephalopathy.

Authors:  Laura M Stinton; Saumya Jayakumar
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

Review 6.  Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Authors:  Lise L Gluud; Rebecca Jeyaraj; Marsha Y Morgan
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

Review 7.  Management of overt hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-10

Review 8.  Minimal hepatic encephalopathy impairs quality of life.

Authors:  Swastik Agrawal; Sridharan Umapathy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-04

Review 9.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

10.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Authors:  Ganesh Pantham; Anthony Post; Deepak Venkat; Douglas Einstadter; Kevin D Mullen
Journal:  Dig Dis Sci       Date:  2017-05-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.